Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/48620
Campo DC Valoridioma
dc.contributor.authorPérez de Diego, Rebecaen_US
dc.contributor.authorRodríguez-Gallego, Carlosen_US
dc.date.accessioned2018-11-23T23:27:37Z-
dc.date.available2018-11-23T23:27:37Z-
dc.date.issued2014en_US
dc.identifier.isbn9780124058606en_US
dc.identifier.urihttp://hdl.handle.net/10553/48620-
dc.description.abstractIRAK-4 and MyD88 deficiencies abolish the responses mediated by all Toll-like receptors (TLRs), except the responses to TLR-3 and some TLR-4-mediated responses, as well as IL-1 receptor-mediated responses. IRAK-4- and MyD88-deficient patients suffer from recurrent pyogenic bacterial infections, particularly invasive infections by Streptococcus pneumoniae and, to a lesser extent, Staphylococcus aureus and Pseudomonas aeruginosa. However, they are resistant to other microorganisms. IRAK-4 and MyD88 deficiencies are life-threatening in infancy and childhood. However, infections become rarer with age. A striking feature of IRAK-4 and MyD88 deficiencies is the low or delayed inflammatory responses in the course of infections. Patients with deficiencies of TLR3 immunity, due to mutations in UNC93B1, TLR3, TRIF, TRAF3, or TBK1, have a similar cellular phenotype consisting of impaired TLR3 signaling in fibroblasts, oligodendrocytes, and neurons. Patients suffer from herpes simplex virus-1 encephalitis, without detectable viral dissemination, but they remain normally resistant to other common viruses.en_US
dc.languageengen_US
dc.relation.ispartofStiehm's Immune Deficiencies
dc.sourceStiehm's Immune Deficiencies, p. 687-710en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject.otherToll-like receptorsen_US
dc.subject.otherPyogenic bacterial infectionsen_US
dc.subject.otherFibroblastsen_US
dc.subject.otherOligodendrocytesen_US
dc.subject.otherNeuronsen_US
dc.titleOther TLR Pathway Defectsen_US
dc.typeinfo:eu-repo/semantics/bookParten_US
dc.typeBooken_US
dc.identifier.doi10.1016/B978-0-12-405546-9.00034-0en_US
dc.identifier.scopus84943402496-
dc.contributor.authorscopusid6602362424-
dc.contributor.authorscopusid6602114379-
dc.description.lastpage710en_US
dc.description.firstpage687en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Capítulo de libroen_US
dc.description.numberofpages24en_US
dc.utils.revisionen_US
dc.date.coverdateAgosto 2014en_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.contributor.buulpgcBU-MEDen_US
dc.contributor.buulpgcBU-MEDen_US
dc.contributor.buulpgcBU-MEDen_US
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-4344-8644-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameRodríguez Gallego, José Carlos-
Colección:Capítulo de libro
Vista resumida

Citas SCOPUSTM   

3
actualizado el 24-nov-2024

Visitas

50
actualizado el 03-feb-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.